Publications by authors named "D F Valla"
Article Synopsis
- ACBP/DBI is a protein linked to metabolic-associated steatohepatitis and liver fibrosis, showing higher levels in affected patients, correlating strongly with NAFLD and FIB4 scores, regardless of age or body mass index.
- A study used a monoclonal antibody to neutralize ACBP/DBI in various mouse models of liver disease, resulting in reduced signs of liver damage and halting disease progression.
- The results suggest ACBP/DBI plays a causal role in liver conditions and could be a potential therapeutic target for treating liver diseases.
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies.
Lancet Gastroenterol Hepatol
September 2024
Portal vein thrombosis (PVT) refers to the development of a non-malignant obstruction of the portal vein, its branches, its radicles, or a combination. This Review first provides a comprehensive overview of all aspects of PVT, namely the specifics of the portal venous system, the risk factors for PVT, the pathophysiology of portal hypertension in PVT, the interest in non-invasive tests, as well as therapeutic approaches including the effect of treating risk factors for PVT or cause of cirrhosis, anticoagulation, portal vein recanalisation by interventional radiology, and prevention and management of variceal bleeding in patients with PVT. Specific issues are also addressed including portal cholangiopathy, mesenteric ischaemia and intestinal necrosis, quality of life, fertility, contraception and pregnancy, and PVT in children.
View Article and Find Full Text PDFThe Laser Megajoule (LMJ) is among the most energetic inertial confinement fusion laser facilities in the world, together with the National Ignition Facility (NIF) in the USA. The construction of the facility began back in 2003, and the first photons were emitted by the laser bundle #28 in 2014. Today, 11 laser bundles consisting of 88 large aperture 0.
View Article and Find Full Text PDFArticle Synopsis
- A study examined the risk of new thrombotic events in patients with non-cirrhotic portal vein thrombosis (NCPVT) linked to local factors after stopping anticoagulation therapy.
- Out of 154 patients assessed, a significant portion had high-risk prothrombotic factors, with new thrombotic events occurring in 17 patients during a median follow-up of 52 months.
- The results suggest that high-risk factors increase the likelihood of new thrombosis, while continuous anticoagulation treatment may reduce these risks effectively.